MDACC Study No:2011-1123 ( NCT No: NCT01542684)
Title:Phase II Study of Azacytidine Followed by GM-CSF in Patients with Low- or Intermediate-1- Risk Myelodysplastic Syndrome (MDS)
Principal Investigator:Zeev Estrov
Treatment Agent:Azacitidine; GM-CSF
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if the combination of
azacitidine and GM-CSF can help to control MDS. The safety of these drugs will
also be studied.

Azacitidine is designed to block certain proteins that stop the function of
tumor-fighting genes. By blocking the "bad" proteins, the tumor-fighting genes
may be able to work better.

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is designed to help
produce white blood cells. This may help to fight infections.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Azacitidine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:N/A
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Zeev Estrov
For Clinical Trial Enrollment:713-704-1675
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults